0001104659-18-025639.txt : 20180420 0001104659-18-025639.hdr.sgml : 20180420 20180420165307 ACCESSION NUMBER: 0001104659-18-025639 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180418 FILED AS OF DATE: 20180420 DATE AS OF CHANGE: 20180420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vaughn Victor CENTRAL INDEX KEY: 0001567077 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 18767317 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 1550 EAST GUDE DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 a4.xml 4 X0306 4 2018-04-18 0 0001356576 SUPERNUS PHARMACEUTICALS INC SUPN 0001567077 Vaughn Victor C/O SUPERNUS PHARMACEUTICALS, INC. 1550 EAST GUDE DRIVE ROCKVILLE MD 20850 0 1 0 0 Sr. VP of Sales & Marketing Common Stock 2018-04-18 4 M 0 6250 12.98 A 15594 D Common Stock 2018-04-18 4 M 0 3750 25.30 A 19344 D Common Stock 2018-04-18 4 S 0 10000 47.0617 D 9344 D Common Stock 2018-04-19 4 M 0 7850 25.30 A 17194 D Common Stock 2018-04-19 4 S 0 7850 49.0261 D 9344 D Employee Stock Option (Right to Buy) 12.98 2018-04-18 4 M 0 6250 0 D 2026-03-01 Common Stock 6250 25000 D Employee Stock Option (Right to Buy) 25.30 2018-04-18 4 M 0 3750 0 D 2027-02-24 Common Stock 3750 46250 D Employee Stock Option (Right to Buy) 25.30 2018-04-19 4 M 0 7850 0 D 2027-02-24 Common Stock 7850 38400 D Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted. The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted. /s/ Gregory S. Patrick, as attorney-in-fact 2018-04-20